Valentina K. Todorova

Assistant Professor

UAMS

Also affiliated: Bulgarian Academy of Sciences (1993–2000); University of Arkansas Medical Center (2009–2021); Wellcome Centre for Molecular Parasitology (1995); Institute of Molecular Biology (2000); Central Arkansas Veterans Healthcare System (2008–2024); Winthrop Rockefeller Foundation (2024); Arkansas Department of Agriculture (2011); University of Glasgow (1995)

Faculty Researcher

Internal Med, College of Medicine

18 h-index 39 pubs 818 cited

Research Areas

Biomedical Subjects

Links

Research Group UAMS TRI Profile

OverviewAI-generated summary

Valentina K. Todorova, Assistant Professor in Internal Medicine at the University of Arkansas for Medical Sciences, focuses her research on understanding and predicting the adverse effects of cancer therapies. Her work investigates cardiotoxicity induced by anthracyclines, such as doxorubicin, in breast cancer patients. Todorova's research explores the role of neutrophils and the endothelium in subclinical cardiotoxicity and examines metabolic phenotypes associated with these effects. She also investigates circulating exosomal microRNAs and protein profiles as potential biomarkers for predicting treatment response and toxicity in breast cancer and hepatocellular carcinoma. Her publications include studies on RNA sequencing of heart tissue to understand chemotherapy-induced cardiotoxicity and reviews on predictive biomarkers for treatment response in breast cancer. Todorova has an h-index of 18 with 39 total publications and 801 total citations. She collaborates with researchers including Jeanne Y. Wei, Nathan S. Reyna, Stephanie D. Byrum, and Allen Gies.

Metrics

h-index: 18
Publications: 39
Citations: 818

Selected Publications

Neutrophil Biomarkers Can Predict Cardiotoxicity of Anthracyclines in Breast Cancer (2024)

International Journal of Molecular Sciences 13 citations DOI OpenAlex
RNA sequencing of formalin fixed paraffin-embedded heart tissue provides transcriptomic information about chemotherapy-induced cardiotoxicity (2024)

Pathology - Research and Practice 1 citation DOI OpenAlex
Abstract 3625: Metabolic phenotypes of doxorubicin-induced cardiotoxicity in breast cancer patients (2024)

Cancer Research DOI OpenAlex
Review of: "Effect of neutrophil-to-lymphocyte ratio and vitamin D3 levels on the pathological complete response after neoadjuvant treatment in TNBC and HER2-positive early breast cancer – results of a prospective study" (2023)

DOI OpenAlex
Exosomal MicroRNA and Protein Profiles of Hepatitis B Virus-Related Hepatocellular Carcinoma Cells (2023)

International Journal of Molecular Sciences 12 citations DOI OpenAlex
Circulating Exosomal microRNAs as Predictive Biomarkers of Neoadjuvant Chemotherapy Response in Breast Cancer (2022)

Current Oncology 43 citations DOI OpenAlex
Subclinical doxorubicin-induced cardiotoxicity update: role of neutrophils and endothelium. (2021)

PubMed 14 citations OpenAlex
Biomarkers of inflammation, hypercoagulability and endothelial injury predict early asymptomatic doxorubicin-induced cardiotoxicity in breast cancer patients. (2020)

PubMed 49 citations OpenAlex
Abstract LB-174: Genome-wide DNA methylation signatures predict the early asymptomatic doxorubicin-induced cardiotoxicity in breast cancer (2020)

Cancer Research DOI OpenAlex
Abstract LB-341: Circulating exosomal microRNAs as promising early biomarkers of neoadjuvant chemotherapy response in breast cancer (2020)

Cancer Research DOI OpenAlex
Genome-wide DNA methylation signatures to predict pathologic complete response from combined neoadjuvant chemotherapy with bevacizumab in breast cancer (2020)

PLoS ONE 16 citations DOI OpenAlex
Dantrolene Attenuates Cardiotoxicity of Doxorubicin Without Reducing its Antitumor Efficacy in a Breast Cancer Model (2020)

Translational Oncology 26 citations DOI OpenAlex
Abstract 815: Genome-wide DNA methylation signatures to predict pathologic complete response from combined neoadjuvant chemotherapy with bevacizumab in breast cancer (2019)

Cancer Research DOI OpenAlex
Abstract 815: Genome-wide DNA methylation signatures to predict pathologic complete response from combined neoadjuvant chemotherapy with bevacizumab in breast cancer (2019)

Molecular and Cellular Biology / Genetics DOI OpenAlex
Tumor-endothelial cell interaction in an experimental model of human hepatocellular carcinoma (2018)

Experimental Cell Research 16 citations DOI OpenAlex

View all publications on OpenAlex →

Grants & Funding

As listed on this researcher's institutional profile.

Center for Studies of Host Response to Cancer Therapy NIH Co-Investigator
Advancing Breast Cancer Treatment through Suppression of Chemo-Resistance UAMS Executive Breast Committee Principal Investigator
Arkansas Claude Pepper Older Americans Independence Center at UAMS NIH Co-Investigator
TCIA Sustainment and Scalability - Platforms for Quantitative Imaging Informatics in Precision Medicine NIH Co-Investigator
Dietary glutamine and protection against doxorubicin and cyclophosphamide toxicity Susan G. Komen for the Cure Principal Investigator